FDA, Novo Nordisk and diabetes drugs

Novo’s Weight Loss Drugs Removed from FDA Shortage List
The FDA said weight-loss and diabetes drugs Wegovy and Ozempic are no longer on shortage list. The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs,
Shortage of Novo Nordisk's Wegovy and Ozempic drugs is resolved, FDA says
The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the injections over the next few months.
FDA says Ozempic shortage is over, chilling boom in off-brand versions
The FDA has now resolved the shortages of Novo Nordisk’s and Eli Lilly’s blockbuster weight-loss drugs, which could spell the end to the booming market for cheaper versions made by pharmacies.
Ozempic and Wegovy are no longer in shortage, FDA says
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration said on Friday.
FDA announces end to Wegovy and Ozempic drug shortages, but it could mean higher prices
The FDA has announced that the shortage of Wegovy and Ozempic, medications used for weight loss and diabetes management, is over.
Novo Nordisk Shares Rise After FDA Clears Shortage of Anti-Obesity Drugs
Shares of obesity-drug maker Novo Nordisk rose Friday after the Food and Drug Administration declared that the company’s popular medications Ozempic and Wegovy were no longer in shortage. A shortage o
Shortage of Novo Nordisk’s (NVO) Weight Loss Drugs Is Resolved, Says FDA
The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration
Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper compounded versions
Ozempic and Wegovy officially moved off FDA’s drug shortage list
Ozempic and Wegovy, the widely popular forms of semaglutide sold to treat diabetes and obesity, have officially been removed from the Food and Drug Administration’s (FDA) drug shortage list
Ozempic and Wegovy shortage ends, setting up weight loss drug showdown
Ozempic and Wegovy, the popular GLP-1 drugs for diabetes and weight loss, are no longer in short supply, the FDA declared Friday. Why it matters: That's good news for Novo Nordisk (whose stock rose 5% Friday) and potentially bad news for Hims & Hers (which fell 26%).
Novo’s Ozempic Shortage Is Declared Over, Hitting Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s ...
Why Novo Nordisk Stock Popped on Friday
Novo Nordisk ( NVO 5.29%) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly ...
FiercePharma2d
Novo Nordisk's semaglutide shortage officially concludes in the US, spelling major threat for weight loss drug compounders
Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...